ID1 and neoplasm: These findings uncover the TRIM21‐ID1‐TCF12‐SLC31A1 axis as a critical pathway in ESCC progression, suggesting that targeting this axis with Sorafenib can offer a promising therapeutic strategy for inhibiting tumor growth and improving patient outcomes.